Zelluna ASA ZLNA

Oslo, 20 August 2026 – Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the second quarter 2026. Webcast scheduled for 20 August 2026 at 09:00 (CEST). Link to webcast here. Operational Highlights: First patient dosed with ZI-MA4-1: On 13 July 2026, Zelluna announced the dosing of the first patient in the Phase 1 ZIMA-101 study, marking

Independent Data Monitoring Committee (IDMC) recommends recruitment of the next two patients at the first dose levelFirst patient completed the planned first treatment cycle with no serious adverse events or dose-limiting toxicities observedStudy progressing as planned following favourable initial safety review 17 August 2026 – Zelluna ASA (OSE: ZLNA) today announced that the Independent Data Monitoring Committee (IDMC) has completed its review of the first patient’s safety data from the first-i

Oslo, 17 August 2026: The Board of Directors of Zelluna ASA (the “Company”) hereby calls for an Extraordinary General Meeting to be held on 9 September 2026 at 13:00 CEST, regarding election of a new member of the Company’s Board of Directors (the “Board”). The Nomination Committee has proposed Martin Welschof for election as a new member of the Board. Martin Welschof is CEO of BioInvent International AB (Nasdaq Stockholm) and has previously served as CEO of Affitech A/S and Opsona Therapeutics.

First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation TrustZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical developmentZIMA-101 represents the first clinical evaluation of Zelluna's proprietary TCR-NK platformPatient identification, pre-screening and screening activities continue across all four tumour indications included in the study Company on track for initial clinical data to emerge from mid-2026 July 13 2026 – Zelluna ASA (

Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Research Council of Norway has approved a grant of NOK 16 million to Zelluna under the Innovation Project for the Industrial Sector (IPN) scheme. NOK 16 million grant awarded by the Research Council of NorwayFunding will support Zelluna's ongoing Phase 1 clinical study, ZIMA-101The IPN s

Oslo, 29 June 2026: Reference is made to the stock exchange announcement by Zelluna ASA (the "Company") on 18 June 2026 regarding completion of a private placement of 3,143,958 new shares at a subscription price of NOK 18.50 per share (the "Private Placement"). In connection with the Private Placement, Radforsk Investeringsstiftelse and Gjelsten Holding AS entered into a share lending agreement with ABG Sundal Collier ASA, acting as manager (the “Manager”), and the Company, to facilitate deliver

The Royal Marsden NHS Foundation Trust activated as the second clinical site in the ZIMA-101 Phase 1 trialPatient identification, pre-screening and screening activities ongoing at first activated siteCompany remains on track for initial clinical data to emerge from mid-2026 Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that The Royal Marsden

Oslo, 18 June 2027: Reference is made to the stock exchange announcement published by Zelluna ASA (the "Company") on 17 June 2026 regarding completion of a placement of 3 143 958 new shares at a subscription price of NOK 18.50 (the "Subscription Price") per new share (the "Private Placement"). Radforsk Investeringsstiftelse, a foundation closely associated with Anders Tuv (Chairman of the Board of the Company), has been allocated 162 162 shares in the Private Placement at the Subscription Price.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Zelluna ASA: Private Placement and Retail Offering successfully placed Private Placement and Retail Offering successfully completed, raising

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data Highlights Financing

Oslo, Norway, 27 March 2026 - Anders Tuv, Managing Director in Radforsk Invest, and Chairperson and co-founder of Zelluna ASA (Zelluna), has today entered into an agreement with Radforsk Investeringsstiftelse (Radforsk) pursuant to which Mr. Tuv has been granted options (the Options) to acquire up to 200,000 shares held by Radforsk in Zelluna. Each Option provides a right to acquire one share in Zelluna from Radforsk at an exercise price of NOK 18.5 per share (subject to customary adjustments).

Oslo, Norway – 26 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, invites investors, analysts and other stakeholders to attend its Capital Markets Update on 14 April 2026 (11:30–13:00 CET). At the event the company will present progress on its TCR-NK off-the-shelf cell therapy platform and ongoing clinical activities, including perspectives on early clinical data and

Oslo, Norway, 09 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a collaboration with Etcembly Ltd, a biotechnology company applying advanced machine learning to T cell receptor (TCR) discovery and engineering. Highlights: AI-enabled collaboration to engineer KKLC1-targeting TCRs for Zelluna's TCR-NK platformBuilds on successful engineering of MAGE-A4